C-去甲阿替洛尔 | 1797116-92-7

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: C-去甲阿替洛尔
• 英文名称: Cis-Desmethyl Atenolol
• 英文别名: 2-[4-[3-(ethylamino)-2-hydroxypropoxy]phenyl]acetamide
• CAS: 1797116-92-7
• 化学式: C₁₃H₂₀N₂O₃
• 分子量: 252.31
• InChiKey: BXEVWKYWEMQUHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  84.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Oligomer-beta blocker conjugates
  申请人：Nektar Therapeutics

  公开号：US10251959B2

  公开（公告）日：2019-04-09

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

  本发明提供了通过共价连接水溶性低聚物进行化学修饰的小分子药物。本发明的共轭物在通过多种给药途径中的任何一种给药时，与未附着水溶性低聚物的小分子药物的生物膜穿越率相比，表现出不同的生物膜穿越率。
• METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENETIC TARGETING
  申请人：Liggett Stephen B.

  公开号：US20120289573A1

  公开（公告）日：2012-11-15

  The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
• OLIGOMER-BETA BLOCKER CONJUGATES
  申请人：Nektar Therapeutics

  公开号：US20170360948A1

  公开（公告）日：2017-12-21

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.